Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.

Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.

BACKGROUND:Pancreatic cancer is a highly malignant disease with an extremely poor prognosis. Histone deacetylase inhibitors (HDACIs) have shown promising antitumor activities against preclinical models of pancreatic cancer, either alone or in combination with chemotherapeutic agents. In this study,...

Full description

Bibliographic Details
Main Authors: Guan Wang, Jing He, Jianyun Zhao, Wenting Yun, Chengzhi Xie, Jeffrey W Taub, Asfar Azmi, Ramzi M Mohammad, Yan Dong, Wei Kong, Yingjie Guo, Yubin Ge
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3522644?pdf=render

Internet

http://europepmc.org/articles/PMC3522644?pdf=render

Similar Items